4 terminated. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Terminated 4 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation Indocyanine green, SPY Portable Handheld Imaging - Parathyroid Dysfunction, Adenoma | Phase 4 | Terminated | University of Alabama at Birmingham | 417 | 2024-04-11 | 2026-05-06 |
| Dose Individualization of Pemetrexed - IMPROVE-II Pemetrexed - Non Small Cell Lung Cancer, Mesothelioma | Phase 4 | Terminated | Radboud University Medical Center | 81 | 2019-02-01 | 2022-05-13 |
| Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding octreotide, No Octreotide - Adenoma | Phase 4 | Terminated | AdventHealth | 33 | 2014-03-01 | 2020-07-16 |
| A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) MK0966; rofecoxib / Duration of Treatment: 24 weeks, Comparator: placebo / Duration of Treatment: 24 weeks - Adenomatous Polyposis Coli | Phase 4 | Terminated | Merck Sharp & Dohme LLC | 62 | 2002-08-06 | 2019-09-20 |
Adenomatous Polyposis Coli (1) · Cancer Pain (1) · Carcinoma, Non-Small-Cell Lung (1) · Mesothelioma (1) · Osteoarthritis (1) · Parathyroid Diseases (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms by Site (2) · Adenomatous Polyps (1) · Arthritis (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine System Diseases (1)
Drug Evaluation (1) · Duration of Therapy (1) · Indocyanine Green (1) · Octreotide (1) · Pemetrexed (1) · rofecoxib (1)
AdventHealth (1) · Merck Sharp & Dohme LLC (1) · Radboud University Medical Center (1) · University of Alabama at Birmingham (1)
United States (2) · Netherlands (1)
Herbert Chen, MD (1) · Rob ter Heine, PhD (1) · Robert Hawes, MD (1)